Leukaemogenic mechanism of human T-cell leukaemia virus type I

Reviews in Medical Virology

Volumn 17, Issue 5, 2007, Pages 301-311

  Yasunaga, Jun Ichirou ^a   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEIN P21; PROTEIN P30; REX PROTEIN; TAX PROTEIN;

APOPTOSIS; CELL CONTACT; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DNA MICROARRAY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IMMUNE SYSTEM; LEUKEMOGENESIS; NONHUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENE; T CELL LEUKEMIA; T LYMPHOCYTE; VIRUS TRANSMISSION;

BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA; VIRAL PROTEINS;

EID: 34548758526     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.548     Document Type: Review

References (94)

1. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003; 22: 5131-5140.
2. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000; 18: 109-119.
3. Takatsuki K. Discovery of adult T-cell leukemia. Retrovirology 2005; 2: 16.
4. Yamamoto N, Okada M, Koyanagi Y, et al. Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science 1982; 217: 737-739.
5. Fan N, Gavalchin J, Paul B, et al. Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I. J Clin Microbiol 1992; 30: 905-910.
6. Bangham CR. Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control. Int J Hematol 2003; 78: 297-303.
7. Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299: 1713-1716.
8. Ichimaru M, Ikeda S, Kinoshita K, et al. Mother-to-child transmission of HTLV-1. Cancer Detect Prev 1991; 15: 177-181.
9. Ando Y, Ekuni Y, Matsumoto Y, et al. Long-term serological outcome of infants who received frozen-thawed milk from human T-lymphotropic virus type-I positive mothers. J Obstet Gynaecol Res 2004; 30: 436-438.
10. Miyazato P, Yasunaga J, Taniguchi Y, et al. De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice. J Virol 2006; 80: 10683-10691.
11. Etoh K, Tamiya S, Yamaguchi K, et al. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res 1997; 57: 4862-4867.
12. Etoh K, Yamaguchi K, Tokudome S, et al. Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Int J Cancer 1999; 81: 859-864.
13. Iga M, Okayama A, Shiver S, et al. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis 2002; 185: 691-695.
14. Franchini G, Fukumoto R, Fullen JR. T-cell control by human T-cell leukemia/lymphoma virus type 1. Int J Hematol 2003; 78: 280-296.
15. Gaudray G, Gachon F, Basbous J, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002; 76: 12813-12822.
16. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19: 475-496.
17. Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005; 24: 5976-5985.
18. Akagi T, Ono H, Shimotohno K. Characterization of T cells immortalized by Taxi of human T-cell leukemia virus type 1. Blood 1995; 86: 4243-1249.
19. Hinrichs SH, Nerenberg M, Reynolds RK, et al. A transgenic mouse model for human neurofibromatosis. Science 1987; 237: 1340-1343.
20. Nerenberg M, Hinrichs SH, Reynolds RK, et al. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science 1987; 237: 1324-1329.
21. Grossman WJ, Kimata JT, Wong FH, et al. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1995; 92: 1057-1061.
22. Hasegawa H, Sawa H, Lewis MJ, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med 2006; 12: 466-472.
23. Green JE, Hinrichs SH, Vogel J, et al. Exocrinopathy resembling Sjogren's syndrome in HTLV-1 tax transgenic mice. Nature 1989; 341: 72-74.
24. Iwakura Y, Tosu M, Yoshida E, et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 1991; 253: 1026-1028.
25. Kwon H, Ogle L, Benitez B, et al. Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem 2005; 280: 35713-35722.
26. Kannagi M, Ohashi T, Harashima N, et al. Immunological risks of adult T-cell leukemia at primary HTLV-I infection. Trends Microbiol 2004; 12: 346-352.
27. Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 2004; 109: 559-567.
28. Furukawa Y, Kubota R, Tara M, et al. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001; 97: 987-993.
29. Koiwa T, Hamano-Usami A, Ishida T, et al. 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol 2002; 76: 9389-9397.
30. Taniguchi Y, Nosaka K, Yasunaga J, et al. Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology 2005; 2: 64.
31. Tamiya S, Matsuoka M, Etoh K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996; 88: 3065-3073.
32. Miyazaki M, Yasunaga JI, Taniguchi Y, et al. Preferential selection of HTLV-1 provirus lacking the 5′LTR during oncogenesis. J Virol 2007; 81: 5714-5723.
33. Inoue J, Seiki M, Yoshida M. The second pX product p27 chi-III of HTLV-1 is required for gag gene expression. FEBS Lett 1986; 209: 187-190.
34. Hidaka M, Inoue J, Yoshida M, et al. Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins. EMBO J 1988; 7: 519-523.
35. Collins ND, Newbound GC, Albrecht B, et al. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood 1998; 91: 4701-4707.
36. Albrecht B, Collins ND, Burniston MT, et al. Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 2000; 74: 9828-9835.
37. Mulloy JC, Crownley RW, Fullen J, et al. The human T-cell leukemia/lymphotropic virus type 1 p12I proteins bind the interleukin-2 receptor beta and gammac chains and affects their expression on the cell surface. J Virol 1996; 70: 3599-3605.
38. Nicot C, Mulloy JC, Ferrari MG, et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 2001; 98: 823-829.
39. Ding W, Albrecht B, Luo R, et al. Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin. J Virol 2001; 75: 7672-7682.
40. Johnson JM, Nicot C, Fullen J, et al. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J Virol 2001; 75: 6086-6094.
41. Bartoe JT, Albrecht B, Collins ND, et al. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol 2000; 74: 1094-1100.
42. Zhang W, Nisbet JW, Albrecht B, et al. Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/ p300. J Virol 2001; 75: 9885-9895.
43. Nicot C, Dundr M, Johnson JM, et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004; 10: 197-201.
44. Awasthi S, Sharma A, Wong K, et al. A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions. Mol Cell Biol 2005; 25: 6178-6198.
45. Lefebvre L, Vanderplasschen A, Ciminale V, et al. Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase. J Virol 2002; 76: 1400-1414.
46. Hiraragi H, Michael B, Nair A, et al. Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosis. J Virol 2005; 79: 9449-9457.
47. Larocca D, Chao LA, Seto MH, et al. Human T-cell leukemia virus minus strand transcription in infected T-cells. Biochem Biophys Res Commun 1989; 163: 1006-1013.
48. Lemasson I, Lewis MR, Polakowski N, et al. Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription. J Virol 2007; 81: 1543-1553.
49. Basbous J, Arpin C, Gaudray G, et al. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem 2003; 278: 43620-43627.
50. Matsumoto J, Ohshima T, Isono O, et al. HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene 2005; 24: 1001-1010.
51. Hivin P, Basbous J, Raymond F, et al. The HBZ-SP1 isoform of human T-cell leukemia virus type I represses JunB activity by sequestration into nuclear bodies. Retrovirology 2007; 4: 14.
52. Thebault S, Basbous J, Hivin P, et al. HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett 2004; 562: 165-170.
53. Satou Y, Yasunaga J, Yoshida M, et al. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006; 103: 720-725.
54. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79: 477-480.
55. Cesarman E, Chadburn A, Inghirami G, et al. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/ lymphoma shows frequent p53 mutations. Blood 1992; 80: 3205-3216.
56. Nishimura S, Asou N, Suzushima H, et al. p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. Leukemia 1995; 9: 598-604.
57. Hatta Y, Hirama T, Miller CW, et al. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/ MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699-2704.
58. Uchida T, Kinoshita T, Watanabe T, et al. The CDKN2 gene alterations in various types of adult T-cell leukaemia. Br J Haematol 1996; 94: 665-670.
59. Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or pl6 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 1997; 15: 1778-1785.
60. Nosaka K, Maeda M, Tamiya S, et al. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res 2000; 60: 1043-1048.
61. Morosetti R, Kawamata N, Gombart AF, et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995; 86: 1924-1930.
62. Hatta Y, Yamada Y, Tomonaga M, et al. Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL). Leukemia 1997; 11: 984-989.
63. Takeuchi S, Takeuchi N, Tsukasaki K, et al. Mutations in the retinoblastoma-related gene RB2/p130 in adult T-cell leukaemia/lymphoma. Leuk Lymphoma 2003; 44: 699-701.
64. Tamiya S, Etoh K, Suzushima H, et al. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 1998; 91: 3935-3942.
65. Maeda T, Yamada Y, Moriuchi R, et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 1999; 189: 1063-1071.
66. Sanada I, Tanaka R, Kumagai E, et al. Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood 1985; 65: 649-654.
67. Kamada N, Sakurai M, Miyamoto K, et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report. Cancer Res 1992; 52: 1481-1493.
68. Ariyama Y, Mori T, Shinomiya T, et al. Chromosomal imbalances in adult T-cell leukemia revealed by comparative genomic hybridization: gains at 14q32 and 2p16-22 in cell lines. J Hum Genet 1999; 44: 357-363.
69. Tsukasaki K. Genetic instability of adult T-cell leukemia/lymphoma by comparative genomic hybridization analysis. J Clin Immunol 2002; 22: 57-63.
70. Choi YL, Tsukasaki K, O'Neill MC, et al. A genomic analysis of adult T-cell leukemia. Oncogene 2007; 26: 1245-1255.
71. Oshiro A, Tagawa H, Ohshima K, et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006; 107: 4500-4507.
72. Yasunaga J, Taniguchi Y, Nosaka K, et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64: 6002-6009.
73. Yoshida M, Nosaka K, Yasunaga J, et al. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood 2004; 103: 2753-2760.
74. Yang Y, Takeuchi S, Tsukasaki K, et al. Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res 2005; 29: 47-51.
75. Tsuji T, Sugahara K, Tsuruda K, et al. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells. Int J Hematol 2004; 80: 254-260.
76. Morimoto H, Tsukada J, Kominato Y, et al. Reduced expression of human mismatch repair genes in adult T-cell leukemia. Am J Hematol 2005; 78: 100-107.
77. Pise-Masison CA, Radonovich M, Mahieux R, et al. Transcription profile of cells infected with human T-cell leukemia virus type I compared with activated lymphocytes. Cancer Res 2002; 62: 3562-3571.
78. Sasaki H, Nishikata I, Shiraga T, et al. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood 2005; 105: 1204-1213.
79. Miyamoto Y, Yamaguchi K, Nishimura H, et al. Familial adult T-cell leukemia. Cancer 1985; 55: 181-185.
80. Higuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605-612.
81. Tsukasaki K, Miller CW, Kubota T, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001; 61: 3770-3774.
82. Wodarz D, Hall SE, Usuku K, et al. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc R Soc Lond B Biol Sci 2001; 268: 1215-1221.
83. Suzuki S, Uozumi K, Maeda M, et al. Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection. Int J Hematol 2006; 83: 429-432.
84. Kawano N, Shimoda K, Ishikawa F, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 2006; 82: 840-843.
85. Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol 2000; 71: 290-293.
86. Ogata M, Ogata Y, Imamura T, et al. Successful bone marrow transplantation from an unrelated donor in a patient with adult T cell leukemia. Bone Marrow Transplant 2002; 30: 699-701.
87. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 15-20.
88. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005; 105: 4143-4145.
89. Ishikawa T. Current status of therapeutic approaches to adult T-cell leukemia. Int J Hematol 2003; 78: 304-311.
90. Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006; 354: 1758-1759.
91. Yashiki S, Fujiyoshi T, Arima N, et al. HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 2001; 17: 1047-1061.
92. Kato H, Koya Y, Ohashi T, et al. Oral administration of human T-cell leukemia virus type 1 induces immune unresponsiveness with persistent infection in adult rats. J Virol 1998; 72: 7289-7293.
93. Hasegawa A, Ohashi T, Hanabuchi S, et al. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J Virol 2003; 77: 2956-2963.
94. Cavanagh MH, Landry S, Audet B, et al. HTLV-I antisense transcripts initiating in the 3′LTR are alternatively spliced and polyadenylated. Retrovirology 2006; 3: 15.